Scancell founder says the company is ready to commercialise novel medicines to counteract cancer
Scancell’s Chief Executive Officer, Lindy Durrant, recently sat down with Sarah Lowther from focusIR. During the interview Lindy highlights Scancell’s innovative cancer vaccines, SCIB1 and Modi-1, providing a recap of the impressive clinical data seen thus far. She also discusses the Company’s strategy to do deals with major pharmaceutical companies and explores how revenues from Scancell’s pre-clinical antibody platform help mitigate risk by providing non-dilutive cash to drive the Company’s other assets forward in development.
Watch the Interview with Professor Lindy Durrant and focusIR
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.